Cyprotex (LSE:CRX) Inventory-to-Revenue : 0.10 (As of Jun. 2016)

View and export this data going back to 2002. Start your Free Trial

What is Cyprotex Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Cyprotex's Average Total Inventories for the quarter that ended in Jun. 2016 was £0.88 Mil. Cyprotex's Revenue for the six months ended in Jun. 2016 was £8.73 Mil. Cyprotex's Inventory-to-Revenue for the quarter that ended in Jun. 2016 was 0.10.

Cyprotex's Inventory-to-Revenue for the quarter that ended in Jun. 2016 increased from Dec. 2015 (0.09) to Dec. 2015 (0.10)

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Cyprotex's Days Inventory for the six months ended in Jun. 2016 was 82.18.

Inventory Turnover measures how fast the company turns over its inventory within a year. Cyprotex's Inventory Turnover for the quarter that ended in Jun. 2016 was 2.22.

Cyprotex Inventory-to-Revenue Historical Data

The historical data trend for Cyprotex's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyprotex Inventory-to-Revenue Chart

Cyprotex Annual Data

Trend

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Inventory-to-Revenue

Get a 7-Day Free Trial

0.04

0.05

Cyprotex Semi-Annual Data
	Dec06	Jun07	Dec07	Jun08	Dec08	Jun09	Dec09	Jun10	Dec10	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16
Inventory-to-Revenue	Get a 7-Day Free Trial															0.10	0.11	0.11	0.09	0.10

Competitive Comparison of Cyprotex's Inventory-to-Revenue

For the Biotechnology subindustry, Cyprotex's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cyprotex's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cyprotex's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Cyprotex's Inventory-to-Revenue falls into.

Cyprotex Inventory-to-Revenue Calculation

Cyprotex's Inventory-to-Revenue for the fiscal year that ended in Dec. 2015 is calculated as

	Inventory-to-Revenue (A: Dec. 2015 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Dec. 2014 )	+	Total Inventories (A: Dec. 2015 ))	/	count )	/	Revenue (A: Dec. 2015 )
=	( (0.735	+	0.861)	/	2 )	/	15.61
=	0.798					/	15.61
=	0.05

Cyprotex's Inventory-to-Revenue for the quarter that ended in Jun. 2016 is calculated as

	Inventory-to-Revenue (Q: Jun. 2016 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Dec. 2015 )	+	Total Inventories (Q: Jun. 2016 ))	/	count )	/	Revenue (Q: Jun. 2016 )
=	( (0.861	+	0.905)	/	2 )	/	8.726
=	0.883					/	8.726
=	0.10

Cyprotex (LSE:CRX) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Cyprotex's Days Inventory for the six months ended in Jun. 2016 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Jun. 2016 )	/	Cost of Goods Sold (Q: Jun. 2016 )	*	Days in Period
	=	0.883	/	1.961	*	365 / 2
	=	82.18

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Cyprotex's Inventory Turnover for the quarter that ended in Jun. 2016 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Jun. 2016 )	/	Average Total Inventories (Q: Jun. 2016 )
	=	1.961	/	0.883
	=	2.22

Cyprotex Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cyprotex's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyprotex (LSE:CRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyprotex PLC (LSE:CRX) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.cyprotex.com

Cyprotex PLC was incorporated on October 25, 2001. The Company together with its subsidiaries, provides in vitro and in silico ADMET and PK (absorption, distribution, metabolism, excretion, toxicity and pharmacokinetics) information to a number of different industries including the Pharmaceutical, Biotechnology, Cosmetic, Personal Care, Agrochemical, Chemical Industries and Academia. It provides a range of ADME Tox contract research services, which includes ADME screening, Customized ADME assays, Genomic ADME, In silico pharmacokinetics modeling and In vitro toxicology. It also offers integrated drug discovery services in collaboration with Sygnature Discovery and physicochemical profiling services in collaboration with Sirius Analytical. The Company operates in North America, Mainland Europe and United Kingdom.

Cyprotex (LSE:CRX) Headlines

No Headlines